Intraventricular treatment of relapsed and refractory central nervous system (CNS) lymphoma with rituximab.

被引：0
|
作者：
Schulz, H
Pels, H
Hom, E
Thall, A
Engert, A
机构：
[1] Univ Cologne, Clin Internal Med 1, Cologne, Germany
[2] Univ Bonn, Dept Neurol, D-5300 Bonn, Germany
[3] Idec Pharmaceut Corp, Clin Immunol, San Diego, CA USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4725
引用
收藏
页码：249B / 249B
页数：1
相关论文
共 50 条
  • [1] Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma
    Batchelor, T. T.
    Lesser, G. J.
    Grossman, S. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab
    Schulz, H
    Pels, H
    Schmidt-Wolf, I
    Zeelen, U
    Germing, U
    Engert, A
    [J]. HAEMATOLOGICA, 2004, 89 (06) : 753 - 754
  • [3] Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum
    Yasuyuki Miyake
    Yasushi Okoshi
    Takayuki Machino
    Shigeru Chiba
    [J]. International Journal of Hematology, 2010, 92 : 474 - 480
  • [4] Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum
    Miyake, Yasuyuki
    Okoshi, Yasushi
    Machino, Takayuki
    Chiba, Shigeru
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (03) : 474 - 480
  • [5] Pegylated liposomal doxorubicin treatment in patients with refractory or relapsed central nervous system (CNS) lymphoma.
    Calvisi, A
    Palmas, AD
    Lai, P
    Bianchi, A
    Murgia, A
    Gaviano, E
    Noli, AL
    Curreli, L
    Gabbas, A
    [J]. BLOOD, 2002, 100 (11) : 302B - 303B
  • [6] Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma
    Raizer, Jeffrey J.
    Rademaker, Alfred
    Evens, Andrew M.
    Rice, Laurie
    Schwartz, Margaret
    Chandler, James P.
    Getch, Christopher C.
    Tellez, Claudia
    Grimm, Sean A.
    [J]. CANCER, 2012, 118 (15) : 3743 - 3748
  • [7] A prospective study on the circulation and central nervous system after primary central nervous system B cell lymphoma treatment with rituximab.
    Lin, Tongyu
    Peng, Chen
    Liu, Shu
    Guo, Cheng-cheng
    Wang, Zhao
    Huang, He
    Fang, Xiaojie
    Hong, Huang Ming
    Ren, Quanguang
    Li, Fangfang
    Li, Xue Ying
    Tian, Ying
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab
    Pels, H
    Schulz, H
    Manzke, O
    Hom, E
    Thall, A
    Engert, A
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2002, 59 (03) : 213 - 216
  • [9] Intraventricular and Intravenous Treatment of a Patient with Refractory Primary CNS Lymphoma using Rituximab
    H. Pels
    H. Schulz
    O. Manzke
    E. Hom
    A. Thall
    A. Engert
    [J]. Journal of Neuro-Oncology, 2002, 59 : 213 - 216
  • [10] Intraventricular Rituximab in Pediatric CD20-positive Refractory Primary Central Nervous System Lymphoma
    Wada-Shimosato, Yuko
    Ikeda, Junji
    Tsujimoto, Shin-ichi
    Sasaki, Koji
    Yanagimachi, Masakatsu
    Kajiwara, Ryosuke
    Shiba, Norio
    Murata, Hidetoshi
    Kawahara, Nobutaka
    Yamanaka, Shoji
    Tanoshima, Reo
    Ito, Shuichi
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2019, 41 (07) : 571 - 573
12345